COVID-19 associated vasculitis: A systematic review of case reports and case seriesSystematic Review / Meta-analysis Published on 2022-01-132022-10-28 Journal: Annals of Medicine and Surgery [Category] COVID-19, [키워드] age association Case report Case series case sery Clinical improvement complications of COVID-19 conducted Corticosteroid COVID-19 COVID-19 outbreak COVID-19, Coronavirus disease of 2019 died erythematous female form Google Scholar IgA IgA Vasculitis IgA, Immunoglubulin A Intravenous immunoglobulin Kawasaki disease Leukocytoclastic vasculitis LMWH male management Methylprednisolone MOST papular pathophysiology patients Prognosis Rash reported SARS-C0V, Severe Acute Respiratory Syndrome Coronavirus 2 SARS-CoV-2 searched Significant Symptom systematic review Treatment Vasculitis [DOI] 10.1016/j.amsu.2022.103249 PMC 바로가기 [Article Type] Systematic Review / Meta-analysis
Low-molecular-weight heparin use in coronavirus disease 2019 is associated with curtailed viral persistence: a retrospective multicentre observational study코로나바이러스 질병 2019에서 저분자량 헤파린 사용은 바이러스 지속성 감소와 관련이 있습니다: 후향적 다기관 관찰 연구Observational Study Published on 2021-12-012022-09-10 Journal: Cardiovascular Research [Category] SARS, 바이오마커, 임상, [키워드] (cfDNA) 95% confidence interval anticoagulation attenuation Biomarker cell death cell-free DNA cfDNA Chain Reaction Coagulopathy contraindications coronavirus disease Coronavirus disease 2019 Course COVID-19 COVID-19 patient COVID-19-associated coagulopathy D-dimer decrease different time point different time points Effect evaluate evaluated haemostasis hazard ratio heparin Hospitalization Hospitalized hospitalized COVID-19 patient hypercoagulability interquartile interquartile range LMWH Low-molecular-weight heparin marker mechanism Mortality multicentre multivariable Cox regression no effect NOAC oral anticoagulant outcome Patient patients with COVID-19 plasma polymerase chain polymerase chain reaction Quantitative quantitative polymerase chain reaction reduced reduction Region responsible retrospective SARS-CoV-2 viral persistence subset survival the cell Thromboinflammation time Viral viral persistence virus was collected [DOI] 10.1093/cvr/cvab308 PMC 바로가기 [Article Type] Observational Study
PICO Questions and DELPHI Methodology for the Management of Venous Thromboembolism Associated with COVID-19Article Published on 2021-10-222022-10-28 Journal: Viruses [Category] COVID-19, MERS, [키워드] Admission Algorithm Anticoagulant treatment anticoagulation Combination Consensus coronavirus coronavirus disease COVID-19 COVID-19 patient Deep vein thrombosis determine diagnostic discharge disease higher risk hospital hospitalized patient Inflammatory diseases LMWH low molecular weight management methodology oral anticoagulant Patient patients hospitalized patients with COVID-19 pharmacological PICO provide Pulmonary embolism question receiving recommendation Standard dose suggested therapeutic Thromboprophylaxis thrombosis venous thromboembolic venous thromboembolic disease VTE with COVID-19 [DOI] 10.3390/v13112128 PMC 바로가기 [Article Type] Article
Intermediate- vs. Standard-Dose Prophylactic Anticoagulation in Patients With COVID-19 Admitted in Medical Ward: A Propensity Score-Matched Cohort StudyMedicine Published on 2021-10-152022-10-31 Journal: Frontiers in Medicine [Category] COVID-19, [키워드] Anticoagulant anticoagulation cohort of patient COVID-19 COVID-19 patient death evaluate the effect exclusion French Hospitalization Hospitalized In-hospital in-hospital mortality intermediate intermediate dose intermediate-dose group Kaplan–Meier LMWH Microthrombosis Mortality observé occurred Patient patients with COVID-19 Primary outcome Prophylactic prophylactic treatment reduction in regimen Retrospective study SARS-CoV-2 significant difference Standard dose Standard-dose statistically significant difference thrombosis thrombotic thrombotic event treated Treatment treatment group Trigger venous worsening [DOI] 10.3389/fmed.2021.747527 PMC 바로가기 [Article Type] Medicine
Molecular Mechanism of the Anti-Inflammatory Action of HeparinArticle Published on 2021-10-032022-10-29 Journal: International Journal of Molecular Sciences [Category] COVID-19, MERS, SARS, [키워드] Action anti-inflammatory action anti-inflammatory agent applicability Autoimmune diseases bind binding biological activity Cell cellular receptor complex condition COVID-19 CRS Cytokine storm Cytokines heparin high affinity IFNγ IFNγ IL-6 Inflammation Inflammatory influence inhibit Interaction investigated LMWH low-molecular-weight heparin (LMWH) mechanism molecular dynamics molecular mechanism Molecular modelling nucleus overexpression phosphorylated resulting signalling pathway Stat1 stimulated translocation with COVID-19 [DOI] 10.3390/ijms221910730 PMC 바로가기 [Article Type] Article
Comparison of the Effect of Unfractionated Heparin and Enoxaparin Sodium at Different Doses on the Course of COVID-19-Associated CoagulopathyArticle Published on 2021-09-302022-10-29 Journal: International Review of Cell and Molecular Biology [Category] COVID-19, [키워드] 95% CI 95% confidence interval anticoagulant therapy Blood coagulation Coagulopathy contribute Controlled trial Coronavirus infection Course current death dose Effect effective enoxaparin enrolled exacerbate heparin hospitalised include increased mortality increased risk intensive care intubation intubation rate LMWH Mortality multivariate logistic regression no significant difference Odds ratio Patient patients treated Prophylactic prophylactic dose prophylactic doses randomised recommendation reducing Respiratory failure risk Risk factors SARS-CoV-2 severe COVID-19 therapeutic therapeutic dose therapeutic doses Treatment unfractionated heparin [DOI] 10.3390/life11101032 PMC 바로가기 [Article Type] Article
The Cross-Talk between Thrombosis and Inflammatory Storm in Acute and Long-COVID-19: Therapeutic Targets and Clinical CasesCase Report Published on 2021-09-232022-10-28 Journal: Viruses [Category] COVID-19, SARS, [키워드] activate Activation acute phase acute respiratory syndrome addition Adhesion Molecule administration adopted alteration anti-inflammatory properties Anticoagulant anticoagulant therapy Anticoagulants blood chemistry cardiovascular risk Cell characterized circulating clinical clinical expression Coagulation coagulation cascade Coagulation factors coagulation parameter Coagulopathy complicate component Coronavirus-2 COVID-19 COVID-19 patient COVID-19 patients criteria cross-talk cytokine cytokine expression Cytokines death rate Disseminated intravascular coagulation DOAC DOACs Efficacy endothelial damage evaluate factor Xa Growth factors IMPROVE Inflammation Inflammatory inhibit leucocyte LMWH Local long-COVID-19 oral anticoagulant outcomes PARs Patient patients persistence PF4 Platelet promote inflammation prothrombotic state receptor SARS-CoV-2 storm suggested Survivors Symptom syndrome target thrombin Treatment Venous Thromboembolism VTE [DOI] 10.3390/v13101904 PMC 바로가기 [Article Type] Case Report
A Systematic Review and a Meta-Analysis Comparing Prophylactic and Therapeutic Low Molecular Weight Heparins for Mortality Reduction in 32,688 COVID-19 PatientsPharmacology Published on 2021-09-022022-10-31 Journal: Frontiers in Pharmacology [Category] COVID-19, [키워드] 95% CI 95% confidence interval Activation all-cause mortality anticoagulation bleeding coronavirus disease COVID-19 COVID-19 patients dose effective Effectiveness Efficacy Endpoint evaluated hazard heparin heparin treatment heparins higher risk Hospital stay hospitalized COVID-19 patients increased risk LMWH LOS low molecular weight major bleeding Meta-analysis Mortality no difference Observational cohort study Patient patients performed potential therapy Prophylactic prophylactic dose Randomized controlled trial Ratio RCT reduced reducing mortality Registration reported review SARS-CoV2 secondary subgroup analysis systematic review therapeutic dose Thromboembolism Treatment unfractionated heparin was performed weight [DOI] 10.3389/fphar.2021.698008 PMC 바로가기 [Article Type] Pharmacology
Point of care ultrasound (POCUS) in diagnosis of proximal deep vein thrombosis among COVID-19 hospitalized patients with a high rate of low molecular weight heparin prophylaxis저분자량 헤파린 예방치료율이 높은 코로나19 입원환자 근위심부정맥혈전증 진단 시 현장진료초음파(POCUS)Case Reports Published on 2021-08-272022-09-11 Journal: Medicina clínica [Category] SARS, 치료기술, [키워드] anticoagulation Care clinical clinical and laboratory features Complication COVID-19 critical condition Deep vein Deep vein thrombosis detect determine Diagnosis discharged DVT Ecografía Embolia pulmonar English helping heparin Heparina de bajo peso molecular hospitalized COVID-19 patients hospitalized patient ICU intensive care intensive care unit Laboratory features limb LMWH low molecular weight low molecular weight heparin Low-molecular-weight heparin Lower lower limb molecular notable outcome pacientes hospitalizado Patient performed planta Point point-of-care popliteal positive Prescriptions Prevalence Prophylaxis proximal pulmonary Pulmonary embolism receiving screened Screening Sin Spanish suffered thrombosis thrombotic complication Thrombotic complications treat Trombosis venosa profunda Ultrasonography ward was performed were assessed with COVID-19 [DOI] 10.1016/j.medcli.2021.01.012 PMC 바로가기 [Article Type] Case Reports
Clinical outcomes of patients hospitalized for COVID-19 and evidence-based on the pharmacological management reduce mortality in a region of the Colombian CaribbeanObservational Study Published on 2021-06-012022-10-05 Journal: Journal of infection and public health [Category] SARS, 임상, [키워드] Admitted Patient advanced age analyzed ARDS average carried Characteristics clinical Clinical management Colchicine Combination Comorbidities Comorbidity Complication Corticosteroid Corticosteroids COVID-19 COVID-19 drug treatment diagnosis of COVID-19 disease Emerging infectious disease evidenced Factor Health hospitalized patient implementation infections Kidney disease LMWH low molecular weight medication Mortality Mortality determinant mortality rate obesity outcome Patient patients hospitalized pharmacological management Public public health surveillance reduce reduce mortality reducing mortality regimen respiratory SARS-COV-2 infection Sepsis significant difference Sociodemographic characteristics the disease therapeutic Therapeutics Treatment Volume with COVID-19 [DOI] 10.1016/j.jiph.2021.02.013 PMC 바로가기 [Article Type] Observational Study